JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (27)
2024
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
Future Oncology, Vol. 19, Núm. 12, pp. 819-828
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
-
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Journal of Clinical Oncology, Vol. 41, Núm. 18, pp. 3339-3351
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
European Urology, Vol. 82, Núm. 3, pp. 283-292
-
Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning
Oncotarget, Vol. 13, pp. 237-256
-
Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
Cancers, Vol. 14, Núm. 2
-
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373
2021
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
-
Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy
Cancers, Vol. 13, Núm. 11
2020
-
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444
2019
-
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
Critical Reviews in Oncology/Hematology, Vol. 138, pp. 190-206
2018
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2017
-
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9
-
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 435-444
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226